Skip to NavigationSkip to content

News

0
From new and exciting technologies to some very heated controversies, check out the top ten most read articles on Pharmafile.com over the past seven...
0
The first biosimilar of the world’s second best-selling drug is edging closer to release with official FDA approval.
0
Institute recommending the use of Alexion Pharmaceutical’s Strensiq for children with perinatal- and infantile-onset hypophosphatasia.
0
The company's shares fell by 17% as a result of Idalopirdine's failure, its biggest drop in four years.

Features

Paul Ranson, of global law firm Morgan Lewis' London Life Sciences Practice examines how UK biopharma must now adapt to a changing landscape